Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Berodual® Respimat® solution for inhalation

Study type: Observational

Funder types: Industry

Identifiers

NCT02231372

215.1362

Details and patient eligibility

About

Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice

Enrollment: 4,602 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men and women presenting with symptoms of chronic obstructive pulmonary disease
• Both previously untreated patients and patients treated previously with Berodual® or with other anti-obstructive respiratory tract agents may be included

Exclusion criteria

• Patients presenting with the general and specific contraindications listed in the Patient Information Leaflet and the Basic Product Information

Trial design

4,602 participants in 1 patient group

chronic obstructive airways disease patients

Treatment:

Drug: Berodual® Respimat® solution for inhalation